151 related articles for article (PubMed ID: 38138255)
21. Loss of p16 expression and copy number changes of CDKN2A in a spectrum of spitzoid melanocytic lesions.
Harms PW; Hocker TL; Zhao L; Chan MP; Andea AA; Wang M; Harms KL; Wang ML; Carskadon S; Palanisamy N; Fullen DR
Hum Pathol; 2016 Dec; 58():152-160. PubMed ID: 27569296
[TBL] [Abstract][Full Text] [Related]
22. Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant.
Frydenlund N; Leone D; Yang S; Hoang MP; Deng A; Hernandez-Perez M; Singh R; Biswas A; Yaar R; Mahalingam M
Mod Pathol; 2017 Mar; 30(3):357-369. PubMed ID: 28084337
[TBL] [Abstract][Full Text] [Related]
23. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.
Helsing P; Nymoen DA; Ariansen S; Steine SJ; Maehle L; Aamdal S; Langmark F; Loeb M; Akslen LA; Molven A; Andresen PA
Genes Chromosomes Cancer; 2008 Feb; 47(2):175-84. PubMed ID: 18023021
[TBL] [Abstract][Full Text] [Related]
24. Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients.
Mantelli M; Pastorino L; Ghiorzo P; Barile M; Bruno W; Gargiulo S; Sormani MP; Gliori S; Vecchio S; Ciotti P; Sertoli MR; Queirolo P; Goldstein AM; Bianchi-Scarrà G;
Melanoma Res; 2004 Dec; 14(6):443-8. PubMed ID: 15577313
[TBL] [Abstract][Full Text] [Related]
25. Epidemiological features and prognostic parameters of multiple primary melanomas in CDKN2A-mutations patients.
De Giorgi V; Savarese I; D'Errico A; Gori A; Papi F; Colombino M; Sini MC; Grazzini M; Stanganelli I; Rossari S; Covarelli P; Massi D; Palmieri G
Pigment Cell Melanoma Res; 2015 Nov; 28(6):747-51. PubMed ID: 26223839
[No Abstract] [Full Text] [Related]
26. Malignant and benign tumors associated with multiple primary melanomas: just the starting block for the involvement of MITF, PTEN and CDKN2A in multiple cancerogenesis?
Pollio A; Tomasi A; Seidenari S; Pellacani G; Rodolfo M; Frigerio S; Maurichi A; Turchetti D; Bassoli S; Ruini C; Ponti G
Pigment Cell Melanoma Res; 2013 Sep; 26(5):755-7. PubMed ID: 23802662
[No Abstract] [Full Text] [Related]
27. Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations.
Potrony M; Puig-Butille JA; Aguilera P; Badenas C; Tell-Marti G; Carrera C; Javier Del Pozo L; Conejo-Mir J; Malvehy J; Puig S
JAMA Dermatol; 2016 Apr; 152(4):405-12. PubMed ID: 26650189
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological significance of tumor-infiltrating lymphocytes and programmed death-1 expression in cutaneous melanoma: a comparative study on clinical subtypes.
Lee WJ; Lee YJ; Shin HJ; Won CH; Chang SE; Choi JH; Lee MW
Melanoma Res; 2018 Oct; 28(5):423-434. PubMed ID: 29634635
[TBL] [Abstract][Full Text] [Related]
29. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
Pjanova D; Engele L; Randerson-Moor JA; Harland M; Bishop DT; Newton Bishop JA; Taylor C; Debniak T; Lubinski J; Kleina R; Heisele O
Melanoma Res; 2007 Jun; 17(3):185-91. PubMed ID: 17505264
[TBL] [Abstract][Full Text] [Related]
30. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.
Potrony M; Puig-Butillé JA; Aguilera P; Badenas C; Carrera C; Malvehy J; Puig S
J Am Acad Dermatol; 2014 Nov; 71(5):888-95. PubMed ID: 25064638
[TBL] [Abstract][Full Text] [Related]
31. Germline CDKN2A mutations among Greek patients with early-onset and multiple primary cutaneous melanoma.
Stratigos AJ; Yang G; Dimisianos R; Nicolaou V; Stefanaki I; Katsambas AD; Tsao H
J Invest Dermatol; 2006 Feb; 126(2):399-401. PubMed ID: 16374456
[TBL] [Abstract][Full Text] [Related]
32. Germline CDKN2A/p16 mutations are rare in multiple primary and familial malignant melanoma in German patients.
Lukowsky A; Schäfer-Hesterberg G; Sterry W; Voit C
J Dermatol Sci; 2008 Feb; 49(2):163-5. PubMed ID: 17890059
[No Abstract] [Full Text] [Related]
33. Disease-Associated Risk Variants in
Davari DR; Orlow I; Kanetsky PA; Luo L; Edmiston SN; Conway K; Parrish EA; Hao H; Busam KJ; Sharma A; Kricker A; Cust AE; Anton-Culver H; Gruber SB; Gallagher RP; Zanetti R; Rosso S; Sacchetto L; Dwyer T; Ollila DW; Begg CB; Berwick M; Thomas NE;
Cancer Epidemiol Biomarkers Prev; 2021 Dec; 30(12):2309-2316. PubMed ID: 34607836
[TBL] [Abstract][Full Text] [Related]
34. Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients.
De Logu F; Galli F; Nassini R; Ugolini F; Simi S; Cossa M; Miracco C; Gianatti A; De Giorgi V; Rulli E; Cossu A; Massi D; Mandalà M
Cells; 2021 Feb; 10(2):. PubMed ID: 33671367
[TBL] [Abstract][Full Text] [Related]
35. Genotype analysis in Hungarian patients with multiple primary melanoma.
Hatvani Z; Brodszky V; Mazán M; Pintér D; Hársing J; Tóth V; Somlai B; Kárpáti S
Exp Dermatol; 2014 May; 23(5):361-4. PubMed ID: 24660985
[TBL] [Abstract][Full Text] [Related]
36. Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype.
Nielsen K; Harbst K; Måsbäck A; Jönsson G; Borg A; Olsson H; Ingvar C
Melanoma Res; 2010 Aug; 20(4):266-72. PubMed ID: 20526219
[TBL] [Abstract][Full Text] [Related]
37. Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients.
Ghiorzo P; Villaggio B; Sementa AR; Hansson J; Platz A; Nicoló G; Spina B; Canepa M; Palmer JM; Hayward NK; Bianchi-Scarrà G
Hum Pathol; 2004 Jan; 35(1):25-33. PubMed ID: 14745721
[TBL] [Abstract][Full Text] [Related]
38. 99mTc-interleukin-2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: a validation study.
Signore A; Annovazzi A; Barone R; Bonanno E; D'Alessandria C; Chianelli M; Mather SJ; Bottoni U; Panetta C; Innocenzi D; Scopinaro F; Calvieri S
J Nucl Med; 2004 Oct; 45(10):1647-52. PubMed ID: 15471828
[TBL] [Abstract][Full Text] [Related]
39. Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations.
Yang XR; Liang X; Pfeiffer RM; Wheeler W; Maeder D; Burdette L; Yeager M; Chanock S; Tucker MA; Goldstein AM
Fam Cancer; 2010 Dec; 9(4):625-33. PubMed ID: 20574843
[TBL] [Abstract][Full Text] [Related]
40. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
